Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence

Breast cancer is the most common malignancy and the leading cause of cancer death in females worldwide. Treatment is challenging, especially for those who are triple‐negative. Increasing evidence suggests that diverse immune populations are present in the breast tumour microenvironment, which opens...

Full description

Saved in:
Bibliographic Details
Published in:Histopathology 2021-08, Vol.79 (2), p.139-159
Main Authors: Tien, Tracy Z, Lee, Justina N L W, Lim, Jeffrey C T, Chen, Xiao‐Yang, Thike, Aye Aye, Tan, Puay Hoon, Yeong, Joe P S
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - immunology
Breast cancer
Breast Neoplasms - diagnosis
Breast Neoplasms - immunology
Breast Neoplasms - pathology
digital pathology
Fluorescent Antibody Technique - methods
Humans
Immunofluorescence
Immunohistochemistry
Immunohistochemistry - methods
immunotherapy
Labeling
Lymphocytes, Tumor-Infiltrating - immunology
Lymphocytes, Tumor-Infiltrating - pathology
Malignancy
Microenvironments
multiplex imaging
pathology
Prognosis
Therapeutic targets
TILs
Triple Negative Breast Neoplasms - immunology
Triple Negative Breast Neoplasms - pathology
Tumor microenvironment
Tumor Microenvironment - immunology
Tumors
tumour microenvironment
tumour‐infiltrating lymphocytes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer is the most common malignancy and the leading cause of cancer death in females worldwide. Treatment is challenging, especially for those who are triple‐negative. Increasing evidence suggests that diverse immune populations are present in the breast tumour microenvironment, which opens up avenues for personalised drug targets. Historically, our investigations into the immune constitution of breast tumours have been restricted to analyses of one or two markers at a given time. Recent technological advances have allowed simultaneous labelling of more than 35 markers and detailed profiling of tumour‐immune infiltrates at the single‐cell level, as well as determining the cellular composition and spatial analysis of the entire tumour architecture. In this review, we describe emerging technologies that have contributed to the field of breast cancer diagnosis, and discuss how to interpret the vast data sets obtained in order to effectively translate them for clinically relevant use. ​
ISSN:0309-0167
1365-2559
DOI:10.1111/his.14328